Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of DEXTENZA for post-cataract surgery ocular inflammation and pain
CTR20232404Phase 3Active
- Sponsor
- Ocular Therapeutix
- Start
- Sep 2023
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of ozurdex in Postoperative ocular inflammation, post-operative ocular pain, sponsored by Ocular Therapeutix. Started Sep 2023; status: active.
02
Drugs
ozurdex
03
Conditions
Postoperative ocular inflammationpost-operative ocular pain
Beyond the preview
Go deeper on CTR20232404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232404.